RespireRx Pharmaceuticals Inc (fka RSPI)

[enemem]

A couple of things:

People who suffer from ADHD also tend to suffer from SA, so insofar as ampakines blunt SA, there may be a 2-pathway effect on ADHD: directly, via enhanced signalling efficiency at the cortical level, and indirectly, via a reduction of SA-induced sleep disruption, which likely contributes to the ADHD.

The sense I get is that they used a high dose here, to increase the probability of seeing anything at all. A lower dose may have comparable effects on SA, without disrupting sleep as much.

All this is academic. It's not clear at all to me that there is anyone out there willing to risk the time and expense of a full-blown clinical trial for a condition this tricky, in this regulatory environment, regardless of the size of the patient pool.